Syndax Pharmaceuticals (SNDX) EBIT: 2015-2020
Historic EBIT for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' EBIT fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$339.7 million for FY2024, which is 47.71% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its EBIT stood at -$19.9 million for Q4 2020, which was down 0.04% from -$19.9 million recorded in Q3 2020.
- In the past 5 years, Syndax Pharmaceuticals' EBIT ranged from a high of -$8.6 million in Q2 2016 and a low of -$19.9 million during Q4 2020.
- Moreover, its 3-year median value for EBIT was -$17.2 million (2018), whereas its average is -$17.1 million.
- In the last 5 years, Syndax Pharmaceuticals' EBIT crashed by 160.12% in 2016 and then increased by 26.52% in 2019.
- Over the past 5 years, Syndax Pharmaceuticals' EBIT (Quarterly) stood at -$11.1 million in 2016, then slumped by 74.93% to -$19.5 million in 2017, then grew by 0.80% to -$19.3 million in 2018, then climbed by 26.52% to -$14.2 million in 2019, then slumped by 39.81% to -$19.9 million in 2020.
- Its last three reported values are -$19.9 million in Q4 2020, -$19.9 million for Q3 2020, and -$16.6 million during Q2 2020.